HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life.

AbstractBACKGROUND:
The evolution of the IgE response to the numerous allergen molecules of Dermatophagoides pteronyssinus is still unknown.
OBJECTIVES:
We sought to characterize the evolutionary patterns of the IgE response to 12 molecules of D pteronyssinus from birth to adulthood and to investigate their determinants and clinical relevance.
METHODS:
We investigated the clinical data and sera of 722 participants in the German Multicenter Allergy Study, a birth cohort started in 1990. Diagnoses of current allergic rhinitis (AR) related to mite allergy and asthma were based on yearly interviews at the ages of 1 to 13 years and 20 years. IgE to the extract and 12 molecules of D pteronyssinus were tested by means of ImmunoCAP and microarray technology, respectively, in sera collected at ages 1, 2, 3, 5, 6, 7, 10, 13, and 20 years. Exposure to mites at age 6 and 18 months was assessed by measuring Der p 1 weight/weight concentration in house dust.
RESULTS:
One hundred ninety-one (26.5%) of 722 participants ever had IgE to D pteronyssinus extract (≥0.35 kUA/L). At age 20 years, their IgE recognized most frequently Der p 2, Der p 1, and Der p 23 (group A molecules; prevalence, >40%), followed by Der p 5, Der p 7, Der p 4, and Der p 21 (group B molecules; prevalence, 15% to 30%) and Der p 11, Der p 18, clone 16, Der p 14, and Der p 15 (group C molecules; prevalence, <10%). IgE sensitization started almost invariably with group A molecules and expanded sequentially first to group B and finally to group C molecules. Early IgE sensitization onset, parental hay fever, and higher exposure to mites were associated with a broader polymolecular IgE sensitization pattern. Participants reaching the broadest IgE sensitization stage (ie, ABC) had significantly higher risk of mite-related AR and asthma than unsensitized participants. IgE to Der p 1 or Der p 23 at age 5 years or less predicted asthma at school age.
CONCLUSIONS:
Parental hay fever and early exposure to D pteronyssinus allergens promote IgE polysensitization to several D pteronyssinus molecules, which in turn predicts current mite-related AR and current/future asthma. These results might inspire predictive algorithms and prevention strategies against the progression of IgE sensitization to mites toward AR and asthma.
AuthorsDaniela Posa, Serena Perna, Yvonne Resch, Christian Lupinek, Valentina Panetta, Stephanie Hofmaier, Alexander Rohrbach, Laura Hatzler, Linus Grabenhenrich, Olympia Tsilochristou, Kuan-Wei Chen, Carl-Peter Bauer, Ute Hoffman, Johannes Forster, Fred Zepp, Antje Schuster, Ulrich Wahn, Thomas Keil, Susanne Lau, Susanne Vrtala, Rudolf Valenta, Paolo Maria Matricardi
JournalThe Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 139 Issue 2 Pg. 541-549.e8 (02 2017) ISSN: 1097-6825 [Electronic] United States
PMID27793411 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Antigens, Dermatophagoides
  • Immunoglobulin E
Topics
  • Adolescent
  • Adult
  • Age of Onset
  • Animals
  • Antigens, Dermatophagoides (immunology)
  • Asthma (diagnosis, epidemiology, immunology)
  • Child
  • Child, Preschool
  • Cohort Studies
  • Cross Reactions
  • Female
  • Follow-Up Studies
  • Germany (epidemiology)
  • Humans
  • Immunoglobulin E (metabolism)
  • Infant
  • Infant, Newborn
  • Male
  • Predictive Value of Tests
  • Prevalence
  • Prognosis
  • Pyroglyphidae (immunology)
  • Rhinitis, Allergic (diagnosis, epidemiology, immunology)
  • Risk Factors
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: